TAR-210 vs standard bladder chemo for FGFR-mutated bladder cancer
Treatments studied
Part of Cancer, Kidney & urinary, Women’s health & pregnancy clinical trials.
This trial compares a new drug, TAR-210, which is placed directly into the bladder, against standard chemotherapy given through a catheter. It is for people with a specific type of bladder cancer that has a change in the FGFR gene.
Summary written for real people, not researchers, by Clin2.
Who can take part
- You have a type of bladder cancer called intermediate-risk non-muscle invasive bladder cancer (IR-NMIBC).
- Your tumor has a specific change in the FGFR gene (a mutation or fusion).
- All visible tumors have been fully removed by surgery before the study starts.
- You are willing to have regular bladder exams (cystoscopies) and possibly more surgery if the cancer returns.
- You are healthy enough to have a performance status of 0 to 2 (means you can do daily activities with little help).
Quick eligibility check
Answer a few plain-language questions, based on this study's own requirements, to get a preliminary sense of fit.
Similar studies
Other trials that look related to this one.
This trial compares a new drug called TAR-210, given directly into the bladder, to standard chemotherapy for people with a specific type of high-risk bladder cancer that has not invaded muscle. It tests if TAR-210 can be more effective with fewer side effects.
This study looks at how patients with non-muscle invasive bladder cancer are using TAR-200 in everyday medical care. It aims to understand treatment patterns and outcomes outside of a clinical trial.
This trial compares a new medicine called TARA-002, given directly into the bladder, to the doctor's choice of standard chemotherapy. It is for people with a high-grade, non-muscle invasive bladder cancer that has not been treated with BCG or has not had BCG recently.
This trial tests a combination of an immunotherapy drug (toripalimab) with or without two chemotherapy drugs placed directly into the bladder (gemcitabine and mitomycin C). It is for people whose high-risk bladder cancer did not respond to or could not tolerate BCG treatment.
This trial tests a drug called T3011 for a type of bladder cancer that hasn't responded to standard treatments like BCG or chemotherapy. It aims to see if T3011 can help shrink the cancer or keep it from growing, offering a new option for people who have limited choices.
This trial tests a new drug, 2141-V11, for people with bladder cancer that has not gone away after standard treatments like BCG therapy. It may help those with non-muscle invasive bladder cancer or, in one group, muscle-invasive bladder cancer, who cannot have or choose not to have bladder removal surgery.
Hear when a new Non-Muscle Invasive Bladder Neoplasms trial opens
We’ll email you when one opens — at most once a week, no account needed, unsubscribe anytime.